Results: Out of 186 patients with axSpA who started treatment during the study period, 63% were men with a mean age of 54 ± 14.1 years. 75.3% of the patients had radiographic axSpA and 74.7% were HLA-B27 positive. Other baseline characteristics (not shown due to space restrictions). Overall, 80% of the patients achieved ASDAS R/LDA (R36%/LDA44%) in at least one of the visits after 2 years of follow-up, but only 40% (R27%/LDA13%) fulfilled the maintained ASDAS R/LDA state. On the other hand, 73% of patients were classified as BASDAI&CRP R/LDA (R31%/LDA42%) in at least one of the visits, but only 31% (R21%/LDA10%) obtained the maintained BASDAI&CRP R/LDA state. In the multivariate analysis, we observed an independent statistically significant association with male sex (OR=3.19; 95% CI=1.46-6.99), younger age at the beginning of the biological treatment (OR=0.97; 95% CI=0.95-0.99) and the use of methotrexate (OR=3.07; 95% CI=1.39-6.78) in patients who achieved maintained BASDAI&CRP R/LDA and with male sex (OR=4.01; 95% CI=1.83-8.77), younger age at the beginning of the biological therapy (OR=0.96; 95% CI=0.94-0.99) and HLA B27 presence (OR=4.30; 95% CI=1.68-11.01) in patients who achieved maintained ASDAS R/LDA.

Conclusion: Although the majority of patients with axSpA who initiate biological therapy achieve the recommended therapeutic goal in the first two years of treatment, the percentage of patients who manage to maintain the R/LDA status is limited. In our study, maintained R was more frequent than maintained LDA, being somewhat higher when measured by ASDAS. This fact may suggest that patients who achieve maintained R have a greater inhibition of their inflammatory activity and, therefore, it remains in time. Male sex and younger age at the beginning of the biological therapy were the main baseline predictors for achieving maintained R/LDA.

Graphics:

Disclosure of Interests: Karen Nathalie Franco Gomez: None declared, Chaima Plascencia: None declared, Marta Novella-Navarro: None declared, Diego Benavent: None declared, Patricia Bogas: None declared, Romina Nieto: None declared, Irene Monjo: None declared, Laura Nuño: None declared, Alejandro Villalva: None declared, Diana Peiteado Grant/research support from: AbbVie, Lilly, MSD, and Roche, Speakers bureau: AbbVie, Roche, and MSD, Alejandro Balsa Grant/research support from: BMS, Roche, Consultant of: AbbVie, Gilead, Lilly, Pfizer, UCB, Sanofi, Sandoz, Speakers bureau: AbbVie, Lilly, Sanofi, Novartis, Pfizer, UCB, Roche, Nordic, Sandoz, Victoria Navarro-Compán Consultant of: Abbvie, Lilly, Novartis, Pfizer, UCB, Speakers bureau: AbbVie, MSD, Lilly, Novartis, Pfizer, UCB

DOI: 10.1136/annrheumdis-2020-eular.4617

AB0647

THE EFFECT OF EXTRACORPOREAL SHOCK WAVE THERAPY (ESWT) ON PLANTAR FASCIITIS IN PATIENTS WITH AXIAL SPONDYLOARTHROPATHIES: DOUBLE-BLIND, RANDOMIZED CONTROLLED TRIAL

S. Güneş¹, Ö. C. Caner¹, D. Gökmen², Ş. Ataman³, Ş. Kutlay¹. ¹Ankara University School of Medicine, Physical Medicine and Rehabilitation, Ankara, Turkey; ²Ankara University School of Medicine, Biostatistics, Ankara, Turkey; ³Ankara University School of Medicine, Physical Medicine and Rehabilitation, Rheumatology, Ankara, Turkey

Background: The effectiveness and safety of radial extracorporeal shock wave therapy (r-ESWT) on chronic plantar fasciitis (PF) in patients with axial spondyloarthropathies (SpA) remains unclear.

Objectives: To investigate the efficacy and tolerability of r-ESWT in patients with PF in axial-SpA on the clinical and radiological parameters.

Methods: In this double-blind, randomized controlled trial, 22 axial-SpA patients with PF whom have heel pain above 5 according to Visual Analog

Scale (VAS) over 3 months were randomly divided into two groups: r-ESWT (1.8 bar pressure, 10 Hertz frequency, 500 pulse intensity) and sham ESWT. Both groups received a total of 3 treatments at one week intervals. All patients were assessed by using the VAS, heel pressure algometry, Foot Function Index and plantar fascia ultrasonography (thickness, convexity, echogenicity of PF, presence of per fascial fluid and subcutaneous tissue edema) at baseline, one week after each session and 4th and 8th week after the last therapy. A decrease of more than two units on the VAS and improvements on plantar fascia ultrasonographic assessments was considered as primary and secondary endpoints respectively.

Results: Descriptive data of the patients are presented in table 1. Both groups showed significant improvements in all assessment parameters ($p < 0.05$) after the therapy sessions and at the 4th and 8th week follow-up. No serious adverse event was observed in any patient. When two groups were compared regarding the differences in improvements, no statistically significant difference was found between the r-ESWT and sham ESWT groups in any of the parameters ($p > 0.05$).

Table 1. Baseline demographic characteristics of patients

	r-ESWT group (n:10)	Sham group (n:12)
Sex (n, %)		
Female	7 (%70)	9 (%75)
Age* (year)	43.8±8.23	48.5 ± 7.62
Height* (cm)	163.1±7.17	160.75±11.71
Weight* (kg)	80.1±9.38	81.67±22.31
BMI* (kg/cm ²)	30.2±3.92	31.11±5.42
Duration of heel pain n, (%)		
>6 month	8 (%80)	10 (%83.3)
3-6 month	2 (%20)	2 (%16.7)
VAS (0-10)	8.22 ± 1.394	7.82 ± 0.603
FFI scores*		
Right Left	60.66±22.20 51.11±33.37	61.18±21.55 63.18±9.83
Pain	66.66±16.34 51.55±34.20	68.09±27.23 72.27±18.74
Disability		
60.33±31.35		
44.77±41.08		
Activity restriction		
58.72±35.51		
62.36±29.28		
Total	62.66±15.06 49.14±31.60	62.54±25.05
65.90±15.89		
Pressure algometry (kg/cm ²)		
Right Left	2.07 ± 1.58 3.86 ± 4.09	3.70 ± 3.17 3.60 ± 3.23
US measurements*		
Right Left	3.60±0.73 3.40±0.71	4.15±1.07 4.04±1.12
PF thickness (mm)		
Increased PF convexity n (%)	4 (40) 2 (20)	4 (33.3) 5 (41.7)
Decreased echogenicity n (%)	2 (20) 3 (30)	6 (50) 8 (66.7)
Perifascial fluid (+) n (%)	2 (20) 0 (0)	3 (25) 4 (33.3)
Subcutaneous tissue edema (+) n (%)	8 (80) 6 (60)	8 (66.7) 9 (75)

Conclusion: To the best of our knowledge, this is the first study evaluating the clinical and radiological efficacy and tolerability of r-ESWT in patients with PF in axial-SpA. Radial extracorporeal shock wave therapy is safe and tolerable treatment on chronic PF in patients with axial-SpA.

References:

- [1] Dizon JN, Gonzalez-Suarez C, Zamora MT, Gambito ED. Effectiveness of extracorporeal shock wave therapy in chronic plantar fasciitis: a meta-analysis. *Am J Phys Med Rehabil.* 2013 Jul;92(7):606-20

Acknowledgments: None

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.4433

AB0648

COMPARING SYMPTOMS, TREATMENT PATTERNS, AND QUALITY OF LIFE OF ANKYLOSING SPONDYLITIS PATIENTS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN JAPAN

T. Tomita¹, T. Aranishi², K. Hagimori², K. Nakajo², N. Booth³, E. Holdsworth³, T. Hunter⁴. ¹Osaka University, Osaka, Japan; ²Lilly, Kobe, Japan; ³Adelphi, Folkestone, United Kingdom; ⁴Lilly, Indianapolis, United States of America

Background: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease of the axial skeleton associated with impaired health-related quality of life (QoL) and disability.

Objectives: To better understand the symptoms, clinical characteristics, treatment patterns, and quality of life (QoL), of non-radiographic axial spondyloarthritis (nr-axSpA) patients and how they compare to ankylosing spondylitis (AS) patients in Japan.

Methods: Data from a cross-sectional survey conducted with physician (rheumatologists, orthopedic surgeon, and internal medicine) and their consulting